These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 2495578)

  • 1. [Cost effectiveness analysis of cholesterol-reducing measures. Economic analysis of a treatment program].
    Eggen AE; Maehlumshagen PM; Westerheim AB; Kristiansen IS
    Tidsskr Nor Laegeforen; 1989 Mar; 109(7-8):857-63. PubMed ID: 2495578
    [No Abstract]   [Full Text] [Related]  

  • 2. [Socioeconomic aspects of therapy of cardiovascular diseases].
    Lauterbach KW
    Herz; 2000 Aug; 25(5):473-5. PubMed ID: 10992995
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of cardiovascular diseases:a medical-economic approach].
    Therapie; 2001; 56(2):125-30. PubMed ID: 11484713
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of lipid-lowering treatment according to lipid level.
    Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
    Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
    Gaziano TA
    Heart; 2008 Feb; 94(2):140-4. PubMed ID: 18195120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
    Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources].
    Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
    Lakartidningen; 1999 Jun; 96(23):2858-63, 2865-6. PubMed ID: 10405534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
    Rubió PP
    Public Health; 1997 Jan; 111(1):33-40. PubMed ID: 9033222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of preventing cardiovascular diseases.
    Grover SA
    Can J Cardiol; 1999 Dec; 15 Suppl G():114G-6G. PubMed ID: 10692671
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of cardiovascular screening and intervention programmes.
    Anand K; Pandav CS
    Natl Med J India; 1998; 11(1):21-2. PubMed ID: 9557516
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A simple evaluation of prevention against cardiovascular diseases. Patient education is a beneficial expense].
    Bygren LO; Lindholm L; Sjöström M
    Lakartidningen; 1993 Jun; 90(26-27):2460-4. PubMed ID: 8316037
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of public health demonstration programs: the effectiveness and cost-effectiveness of WISEWOMAN.
    Finkelstein EA; Wittenborn JS; Farris RP
    J Womens Health (Larchmt); 2004 Jun; 13(5):625-33. PubMed ID: 15257854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol, children, and heart disease: an analysis of alternatives.
    Berwick DM; Cretin S; Keeler E
    Pediatrics; 1981 Nov; 68(5):721-30. PubMed ID: 6796932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost effectiveness analysis of cholesterol reducing intake].
    Fønnebø V
    Tidsskr Nor Laegeforen; 1989 Apr; 109(12):1325-6. PubMed ID: 2499953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.